MedTrace Logo

Statins and Post-ERCP Acute Pancreatitis (Stark Project)

NCT06367322 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1016

Last updated 2024-04-16

No results posted yet for this study

Summary

Post-endoscopic retrograde cholangiopancrepatography (ERCP) acute pancreatitis (PEAP) is a frequent complication of this endoscopic procedure. Chronic statin intake has been linked to lower incidence and severity of acute pancreatitis (AP). Periprocedural rectal administration of non-steroidal anti-inflammatory drugs is protective against PEP, but the role of chronic acetylsalicylic acid (ASA) treatment is unclear. The aim of the study is to investigate whether statins and chronic ASA intake are associated with lower risk of PEAP.

Conditions

  • Post-ERCP Acute Pancreatitis

Interventions

DRUG

Statin

The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP. Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy.

Sponsors & Collaborators

  • European Pancreatic Club (EPC), Pancreas 2000 Educational Program

    collaborator UNKNOWN

  • Hospital General Universitario de Alicante

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-10
Primary Completion
2018-07-31
Completion
2018-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06367322 on ClinicalTrials.gov